Positive predictive value of respiratory infection diagnoses in the Danish National Patient Registry: A post hoc validation analysis of the DANFLU-1 trial

OBJECTIVES: To validate respiratory infection diagnosis codes in the Danish National Patient Registry (DNPR) in the DANFLU-1 feasibility trial, and to assess whether reperforming effectiveness analyses with validated events altered findings. METHODS: Hospitalizations for influenza or pneumonia (International Classification of Diseases, Tenth Revision codes J09-18) were validated against medical record review by two blinded physicians. Events were validated against (i) medical opinion and (ii) diagnostic criteria of symptomatology combined with laboratory or radiological verification. Positive predictive values (PPVs) were calculated along with relative vaccine effectiveness (rVE) of high-dose (HD) vs standard-dose (SD) influenza vaccines. RESULTS: Among 12,477 participants, we identified 43 events in the DNPR (influenza J09-11: n = 3, pneumonia J12-18: n = 40), which demonstrated PPVs of 86% (95% confidence interval: 72-95%) and 91% (78-97%) against the medical opinion of the respective reviewers. Against diagnostic criteria, the PPVs were 65% (49-79%) and 67% (51-81%). For influenza codes, the PPV was 100% according to reviewers and references and between 63% and 90%, depending on reviewer and reference for pneumonia. The rVE consistently favored HD vs SD against validated events. CONCLUSION: Hospitalizations for pneumonia registered in the DNPR may benefit from subsequent validation, warranting further studies. HD influenza vaccination was associated with fewer validated events than SD. TRIAL REGISTRATION: Clinicaltrials.gov: NCT05048589.

Authors

Institutions

Publication Details

Journal
International Journal of Infectious Diseases
Published
2026-04-13
DOI
https://doi.org/10.1016/j.ijid.2026.108703
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Positive predictive value of respiratory infection diagnoses in the Danish National Patient Registry: A post hoc validation analysis of the DANFLU-1 trial

Joshua Nealon, Julie Inge-Marie Helene Borchsenius, Kristoffer Grundtvig Skaarup, Jacob Christensen et al.
International Journal of Infectious Diseases
Pneumonia and Respiratory Infections
article

Positive predictive value of respiratory infection diagnoses in the Danish National Patient Registry: A post hoc validation analysis of the DANFLU-1 trial

Joshua Nealon, Julie Inge-Marie Helene Borchsenius, Kristoffer Grundtvig Skaarup, Jacob Christensen, Daniel Modin, Kira Hyldekær Janstrup, Niklas Dyrby Johansen, Katrine Feldballe Bernholm, Nino Emanuel Landler, Jens Ulrik Stæhr Jensen, Matthew M. Loiacono, Sandrine Samson, Tor Biering-Sørensen, Martin J. Landray, Carsten Schade Larsen, Brian L. Claggett, Lars Køber, Rebecca Harris, Anne Marie Reimer Jensen, Pradeesh Sivapalan, Scott D. Solomon, Gunnar H. Gislason
article en

Abstract

OBJECTIVES: To validate respiratory infection diagnosis codes in the Danish National Patient Registry (DNPR) in the DANFLU-1 feasibility trial, and to assess whether reperforming effectiveness analyses with validated events altered findings. METHODS: Hospitalizations for influenza or pneumonia (International Classification of Diseases, Tenth Revision codes J09-18) were validated against medical record review by two blinded physicians. Events were validated against (i) medical opinion and (ii) diagnostic criteria of symptomatology combined with laboratory or radiological verification. Positive predictive values (PPVs) were calculated along with relative vaccine effectiveness (rVE) of high-dose (HD) vs standard-dose (SD) influenza vaccines. RESULTS: Among 12,477 participants, we identified 43 events in the DNPR (influenza J09-11: n = 3, pneumonia J12-18: n = 40), which demonstrated PPVs of 86% (95% confidence interval: 72-95%) and 91% (78-97%) against the medical opinion of the respective reviewers. Against diagnostic criteria, the PPVs were 65% (49-79%) and 67% (51-81%). For influenza codes, the PPV was 100% according to reviewers and references and between 63% and 90%, depending on reviewer and reference for pneumonia. The rVE consistently favored HD vs SD against validated events. CONCLUSION: Hospitalizations for pneumonia registered in the DNPR may benefit from subsequent validation, warranting further studies. HD influenza vaccination was associated with fewer validated events than SD. TRIAL REGISTRATION: Clinicaltrials.gov: NCT05048589.

International Journal of Infectious DiseasesVol. 168
Harvard University (US), Aarhus University Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK), Rigshospitalet (DK), Sanofi (France) (FR), University of Oxford (GB), Sanofi (China) (CN), University of Delaware (US)
Sanofi Pasteur
Good health and well-being
Openalex Percentile: Top 29%
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.